Astellas Pharma Inc
TSE:4503
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 446
1 828
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Astellas Pharma Inc stock under the Base Case scenario is 1 795.96 JPY. Compared to the current market price of 1 562 JPY, Astellas Pharma Inc is Undervalued by 13%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Astellas Pharma Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Astellas Pharma Inc cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Astellas Pharma Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Astellas Pharma Inc., a prominent player in the global pharmaceutical industry, has a clear mission: to improve the health of people around the world through innovative technologies and high-quality products. Founded in 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established itself as a leader in areas such as urology, oncology, immunology, and neuroscience. With strong research and development capabilities, the company invests heavily in developing groundbreaking therapies that address unmet medical needs, positioning itself at the forefront of advancements in health sciences. Astellas prides itself on its commitment to sus...
Astellas Pharma Inc., a prominent player in the global pharmaceutical industry, has a clear mission: to improve the health of people around the world through innovative technologies and high-quality products. Founded in 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established itself as a leader in areas such as urology, oncology, immunology, and neuroscience. With strong research and development capabilities, the company invests heavily in developing groundbreaking therapies that address unmet medical needs, positioning itself at the forefront of advancements in health sciences. Astellas prides itself on its commitment to sustainability, ensuring that its operations positively impact society while delivering substantial value to shareholders.
For investors, Astellas represents a compelling opportunity, given its strong financial footing and robust product pipeline. The company boasts a diverse portfolio with several key blockbuster drugs contributing to its steady revenue stream, alongside a promising array of candidates in clinical trials. Furthermore, Astellas actively pursues strategic partnerships and acquisitions to bolster its R&D initiatives and expand its global reach. With a focus on maximizing shareholder value through disciplined financial management and a strategic approach to innovation, Astellas Pharma is not just navigating the complexities of the pharmaceutical landscape; it is shaping the future of healthcare, making it a noteworthy consideration for investors looking for growth in the biotech sphere.
Astellas Pharma Inc. is a global pharmaceutical company based in Japan that focuses on the development and marketing of innovative pharmaceuticals. The company operates primarily in the following core business segments:
-
Oncology: Astellas has a strong focus on oncology therapies, developing medications for various cancer types. This segment includes targeted therapies designed to treat specific cancer mutations and conditions.
-
Urology: This segment predominantly deals with therapies for conditions related to the urinary system, such as overactive bladder and prostate cancer. Astellas is known for its flagship product in this area, which has become a leader in the market.
-
Immunology: The company is engaged in researching and developing advanced therapies for immune-related diseases. This includes both autoimmune diseases and transplant-related therapies, making it a critical area of focus for Astellas.
-
Neuroscience: Astellas is also involved in developing treatments for various central nervous system conditions, including pain management and psychiatric disorders. This segment is a key part of the company’s strategy to diversify its therapeutic focus.
-
Cardiovascular: The company develops medications for various cardiovascular diseases, focusing on improving treatments for conditions such as heart failure and hypertension.
-
Infection: Astellas is engaged in developing novel anti-infective agents to treat severe infections, particularly in hospital settings, addressing the growing concern of antibiotic resistance.
These core segments reflect Astellas Pharma's commitment to addressing significant health challenges and its strategic focus on innovation and research to meet the needs of various patient populations. The company emphasizes collaboration and partnerships in its R&D efforts to bring forward new therapies and expand its pipeline effectively.
Astellas Pharma Inc. has several unique competitive advantages that differentiate it from its rivals in the pharmaceutical industry:
-
Strong Focus on R&D: Astellas invests significantly in research and development, particularly in high-growth areas such as oncology, urology, and immunology. This focus not only helps in developing innovative therapies but also in obtaining patents that provide exclusivity in the market.
-
Pipeline of Innovative Products: The company has a robust pipeline with several promising drug candidates in various stages of development. This pipeline mitigates risks associated with dependence on a few blockbuster drugs and positions Astellas favorably for future growth.
-
Strategic Collaborations and Partnerships: Astellas has formed strategic alliances and collaborations with biotech firms and academic institutions, enabling access to cutting-edge research, technologies, and potential market expansion. These partnerships enhance its innovative capacity and speed to market.
-
Global Presence with Local Expertise: Astellas operates in multiple regions, including North America, Europe, and Asia, allowing it to leverage local market insights and regulatory knowledge. This global presence enables the company to adapt to regional needs and capitalize on diverse markets.
-
Focus on Sustainable Practices: The company emphasizes sustainability and ethical practices, which can improve its reputation and customer loyalty. This commitment resonates with stakeholders and may provide leverage in gaining market share.
-
Strong Financial Position: Astellas has a solid financial base that allows for continued investment in innovation and marketing. This financial strength offers a buffer during downturns and facilitates mergers or acquisitions to further enhance its competitive position.
-
Expertise in Specialty Drugs: Their specialization in niche markets, particularly in complex specialty drugs, positions Astellas as a leader in these fields, providing high-margin products that typically have less competition compared to traditional pharmaceuticals.
-
Patient-Centric Approach: Astellas focuses on patient needs and outcomes, which enhances its brand reputation and fosters loyalty among healthcare providers and patients. This patient-centric approach can lead to better adoption of its products in the market.
-
Regulatory and Market Access Expertise: Astellas has a strong understanding of the regulatory frameworks in the markets where it operates. This expertise helps in navigating the complex approval processes and ensures timely market access for new products.
Together, these advantages create a strong competitive position for Astellas Pharma Inc. in the global pharmaceutical landscape, enabling it to respond effectively to market demands and maintain a leading role in innovation.
Astellas Pharma Inc., like many pharmaceutical companies, faces a variety of risks and challenges that could impact its operations and growth in the near future. Here are some of the key risks and challenges the company may encounter:
-
Patent Expiration and Generic Competition: As patents for key drugs expire, Astellas may face increased competition from generic versions, which could lead to a substantial decline in revenue from those products.
-
Regulatory Challenges: The pharmaceutical industry is heavily regulated. Astellas must navigate the complex regulatory environment to gain approval for new drugs. Delays or rejections from regulatory bodies can significantly impact timelines and financial forecasts.
-
R&D Risk: Research and development (R&D) in pharmaceuticals is inherently risky. There is no guarantee that Astellas's pipeline drugs will successfully complete clinical trials, leading to potential sunk costs without future revenue.
-
Market Dynamics and Pricing Pressure: The pharmaceutical industry is experiencing increased scrutiny regarding drug pricing. Governments and payers are pushing for lower prices, which could affect Astellas's pricing strategies and profit margins.
-
Competition: The pharmaceutical sector is highly competitive. Astellas must innovate consistently to keep up with other pharmaceutical and biotech companies, which may lead to increased R&D expenses.
-
Public Perception and Ethical Considerations: Public opinion regarding pharmaceuticals, including issues like drug pricing, access to medications, and ethical drug marketing, can impact the company’s reputation and business practices.
-
Global Market Risks: Astellas operates internationally, exposing it to exchange rate fluctuations, geopolitical risks, and varying market conditions in different regions, especially in emerging markets.
-
Supply Chain Disruptions: Global events, such as pandemics or geopolitical instability, can disrupt supply chains, affecting the production and distribution of pharmaceuticals, leading to revenue losses.
-
Strategic Alliances and Collaborations: Astellas often collaborates with other companies for research and development. The success of these partnerships is critical, and any failure or discord could impact projects and revenue.
-
Talent Acquisition and Retention: The pharmaceutical industry relies heavily on skilled professionals. Attracting and retaining top talent can be a challenge in a competitive landscape where demand for skilled labor is high.
-
Technological Advancements: Rapid changes in technology and innovations in drug development, including the rise of personalized medicine and advanced therapies, may require Astellas to adapt quickly or risk obsolescence.
By carefully monitoring these risks and developing strategies to mitigate them, Astellas Pharma can strive to maintain its market position and achieve sustainable growth.
Revenue & Expenses Breakdown
Astellas Pharma Inc
Balance Sheet Decomposition
Astellas Pharma Inc
Current Assets | 1.2T |
Cash & Short-Term Investments | 338.6B |
Receivables | 600B |
Other Current Assets | 302B |
Non-Current Assets | 2.5T |
Long-Term Investments | 132.9B |
PP&E | 309.7B |
Intangibles | 1.9T |
Other Non-Current Assets | 105.4B |
Current Liabilities | 1.4T |
Accounts Payable | 173.1B |
Other Current Liabilities | 1.2T |
Non-Current Liabilities | 685.3B |
Long-Term Debt | 443.1B |
Other Non-Current Liabilities | 242.2B |
Earnings Waterfall
Astellas Pharma Inc
Revenue
|
2.1T
JPY
|
Cost of Revenue
|
-383.6B
JPY
|
Gross Profit
|
1.7T
JPY
|
Operating Expenses
|
-1.6T
JPY
|
Operating Income
|
130.6B
JPY
|
Other Expenses
|
-75.9B
JPY
|
Net Income
|
54.6B
JPY
|
Free Cash Flow Analysis
Astellas Pharma Inc
JPY | |
Free Cash Flow | JPY |
Astellas Pharma's Q1 FY 2024 results show revenue increased by 26% year-on-year to JPY 473.1 billion, driven by strong performance in the US. XTANDI sales rose by 29%, contributing significantly. Strategic brands like PADCEV and IZERVAY saw exponential growth, increasing overall strategic brand sales to JPY 75 billion, a threefold increase. Core operating profit also increased by 20.5%, reaching JPY 88.3 billion. Despite the foreign exchange impacts, both revenue and profit grew substantially. The company remains focused on efficient cost management and ROI-driven investments, expecting continued growth throughout the fiscal year.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
Astellas Pharma Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Astellas Pharma Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Astellas Pharma Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Astellas Pharma Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Astellas Pharma Inc
According to Wall Street analysts, the average 1-year price target for Astellas Pharma Inc is 1 983.56 JPY with a low forecast of 1 414 JPY and a high forecast of 2 520 JPY.
Dividends
Current shareholder yield for Astellas Pharma Inc is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 15,455 full-time employees. The firm mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one Astellas Pharma Inc stock under the Base Case scenario is 1 795.96 JPY.
Compared to the current market price of 1 562 JPY, Astellas Pharma Inc is Undervalued by 13%.